trending Market Intelligence /marketintelligence/en/news-insights/trending/sro3EG9PvE3rQVfajdu9rw2 content esgSubNav
In This List

Scholar Rock to get $25M milestone award in fibrosis collaboration with Gilead

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Scholar Rock to get $25M milestone award in fibrosis collaboration with Gilead

Scholar Rock Holding Corp. said it will receive a $25 million payment from Gilead Sciences Inc. as part of a collaboration agreement between the companies.

Cambridge, Mass.-based Scholar Rock and Gilead are collaborating to discover and develop treatments for fibrosis, a disease that scars tissues and vital organs and can be fatal.

The milestone payment was triggered by the successful demonstration of efficacy in preclinical studies of selective inhibitors for latent transforming growth factor-beta, or TGF-B, which is activated in fibrotic diseases.

Under the collaboration, Scholar Rock received $80 million up front — $50 million in cash and $30 million investment in Scholar Rock's common shares — from Gilead. In addition to this milestone payment, Scholar Rock is eligible to receive up to an additional $1.43 billion from Gilead on achieving certain development, regulatory and commercial milestones.

Gilead holds the exclusive option to license worldwide rights to products developed as part of Scholar Rock's three TGF-B programs.

Scholar Rock is responsible for the discovery and preclinical research of potential products, while Gilead after exercising its option will conduct preclinical and clinical development as well as commercialization of the selected programs.